"The US Food and Drug Administration (FDA) has approved tofacitinib citrate extended-release (Xeljanz XR, Pfizer Inc) 11-mg tablets for once-daily treatment of moderate to severe rheumatoid arthritis (RA) in patients who have not responde"...
Patients being started on AZASAN® (azathioprine) should be informed of the necessity of periodic blood counts while they are receiving the drug and should be encouraged to report any unusual bleeding or bruising to their physician. They should be informed of the danger of infection while receiving AZASAN® (azathioprine) and asked to report signs and symptoms of infection to their physician. Careful dosage instructions should be given to the patient, especially when AZASAN® (azathioprine) is being administered in the presence of impaired renal function or concomitantly with allopurinol (see DRUG INTERACTIONS subsection and DOSAGE AND ADMINISTRATION). Patients should be advised of the potential risks of the use of AZASAN® (azathioprine) during pregnancy and during the nursing period. The increased risk of neoplasia following therapy with AZASAN® (azathioprine) should be explained to the patient.
Last reviewed on RxList: 9/14/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Azasan Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options